Basel (Switzerland) and Mannheim (Germany), April 18, 2019 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will present an abstract about the design of its ongoing trial in patients with glioblastoma with VXM01 oral T-cell immunotherapy in combination with the anti-PD-L1 checkpoint inhibitor avelumab at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
2019 ASCO (American Society of Clinical Oncology) Annual Meeting
May 31 – June 4, 2019
Chicago, IL, USA
The abstract (#269161) “Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071” will be presented during Poster Session: Central Nervous System Tumors, on June 2, 2019, 8:00 AM-11:00 AM CDT. The abstract will be available online on May 15, 2019 at 5 PM EDT at http://abstracts.asco.org.
Additionally, the Company will participate in several other industry and scientific events in the second quarter of 2019.
European Neoantigen Summit
April 23 – 25, 2019
Amsterdam, The Netherlands
VAXIMM representatives will be available for one-on-one meetings during the summit. To schedule a meeting with VAXIMM, please contact info@vaximm.com.
Bio€quity Europe
May 20 – 21, 2019
Barcelona, Spain
Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s meeting system.
17th CIMT (Association for Cancer Immunotherapy) Annual Meeting
May 21 – 23, 2019
Mainz, Germany
VAXIMM representatives will be available for one-on-one meetings during the event. To schedule a meeting with VAXIMM, please contact info@vaximm.com.
About VAXIMM
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. CMS has made an equity investment in VAXIMM; the Company’s other investors include BB Biotech Ventures, M Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com.
Contact:
VAXIMM AG
Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
Email: info@vaximm.com
Media Inquiries:
MC Services AG
Katja Arnold, Laurie Doyle
Tel: +49 89 210228 0
Email: vaximm@mc-services.eu
